Wong TW - Search Results

1

IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.

Huang F, Chang H, Greer A, Hillerman S, Reeves KA, Hurlburt W, Cogswell J, Patel D, Qi Z, Fairchild C, Ryseck RP, Wong TW, Finckenstein FG, Jackson J, Carboni JM. Huang F, et al. Among authors: wong tw. Mol Cancer Ther. 2015 Feb;14(2):620-30. doi: 10.1158/1535-7163.MCT-14-0794-T. Epub 2014 Dec 19. Mol Cancer Ther. 2015. PMID: 25527633

2

Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.

Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald P, Fairchild C, Wong T, Wee S. Lenhart R, et al. Mol Cancer Ther. 2015 Oct;14(10):2167-74. doi: 10.1158/1535-7163.MCT-15-0037. Epub 2015 Aug 7. Mol Cancer Ther. 2015. PMID: 26253517

3

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW. Carboni JM, et al. Among authors: wong tw. Cancer Res. 2005 May 1;65(9):3781-7. doi: 10.1158/0008-5472.CAN-04-4602. Cancer Res. 2005. PMID: 15867374

4

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.

Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E. Huang F, et al. Among authors: wong tw. Cancer Res. 2007 Mar 1;67(5):2226-38. doi: 10.1158/0008-5472.CAN-06-3633. Cancer Res. 2007. PMID: 17332353

5

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, Sagar M, Wong TW, Gottardis MM, Erlichman C. Haluska P, et al. Among authors: wong tw. Mol Cancer Ther. 2008 Sep;7(9):2589-98. doi: 10.1158/1535-7163.MCT-08-0493. Epub 2008 Sep 2. Mol Cancer Ther. 2008. PMID: 18765823 Free PMC article.

6

Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.

Roongta UV, Pabalan JG, Wang X, Ryseck RP, Fargnoli J, Henley BJ, Yang WP, Zhu J, Madireddi MT, Lawrence RM, Wong TW, Rupnow BA. Roongta UV, et al. Among authors: wong tw. Mol Cancer Res. 2011 Nov;9(11):1551-61. doi: 10.1158/1541-7786.MCR-11-0126. Epub 2011 Sep 27. Mol Cancer Res. 2011. PMID: 21954435

7

Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models.

Manne V, Lee FY, Bol DK, Gullo-Brown J, Fairchild CR, Lombardo LJ, Smykla RA, Vite GD, Wen ML, Yu C, Wong TW, Hunt JT. Manne V, et al. Among authors: wong tw. Cancer Res. 2004 Jun 1;64(11):3974-80. doi: 10.1158/0008-5472.CAN-03-3849. Cancer Res. 2004. PMID: 15173010

8

Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.

Wong TW, Lee FY, Emanuel S, Fairchild C, Fargnoli J, Fink B, Gavai A, Hammell A, Henley B, Hilt C, Hunt JT, Krishnan B, Kukral D, Lewin A, Malone H, Norris D, Oppenheimer S, Vite G, Yu C. Wong TW, et al. Clin Cancer Res. 2011 Jun 15;17(12):4031-41. doi: 10.1158/1078-0432.CCR-10-3417. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531814

9

Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.

Reilly TP, Graziano MJ, Janovitz EB, Dorr TE, Fairchild C, Lee F, Chen J, Wong T, Whaley JM, Tirmenstein M. Reilly TP, et al. Diabetes Ther. 2014 Jun;5(1):73-96. doi: 10.1007/s13300-014-0053-3. Epub 2014 Jan 29. Diabetes Ther. 2014. PMID: 24474422 Free PMC article.

10

Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics.

Kellar KA, Lorenzi MV, Ho CP, You D, Wen ML, Ryseck RP, Oppenheimer S, Fink BE, Vite GD, Rowley BR, Yu C, Bol DK, Lee FY, Wong TW. Kellar KA, et al. Among authors: wong tw. Mol Cancer Ther. 2006 Jun;5(6):1571-6. doi: 10.1158/1535-7163.MCT-06-0078. Mol Cancer Ther. 2006. PMID: 16818516

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

662 results

Search Page

Filters